Shares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, ...

The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...

Topline results were announced from a phase 3 trial evaluating simufilam, an oral small molecule that targets the filamin A protein, for the treatment of mild to moderate Alzheimer disease (AD).

Simufilam – a small-molecule drug targeting filamin A, a different mechanism to the current crop of amyloid-targeting Alzheimer's therapies – failed to deliver a statistically significant ...

Simufilam, which aims to address Alzheimer’s by targeting the shape of the protein Filamin A rather than amyloid plaques, had drawn significant interest for its novel approach. However ...

Simufilam is Cassava’s proprietary small molecule drug candidate that targets filamin A. The intellectual property that Cassava has licensed is based on the promising research and development ...

Simufilam is Cassava’s proprietary small molecule drug candidate that targets filamin A. “We are pleased to enter into a license agreement with Yale University, based on the research of Dr ...